BPD Program

About AyuVis Research

AyuVis Research, founded in 2016, is a private, preclinical-stage biotech developing first-in-class small molecule immunotherapies that modulate white blood cells to address severe inflammatory and infectious diseases. Its lead programs target unmet needs in respiratory complications like BPD and PAP, with a unique mechanism designed to avoid drug resistance and immunosuppression. The company has secured non-dilutive NIH grant funding, won several entrepreneurial awards, and is preparing for first-in-human clinical trials. Led by founder and CEO Dr. Suchismita Acharya, AyuVis leverages a platform with potential applications across multiple critical care indications.

Therapeutic Areas